|
Market Closed -
Euronext Paris
11:55:00 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 0.8500 EUR | +10.39% |
|
+5.59% | +515.94% |
| 08-17 | Valerio Therapeutics Nears Final Deal for Etherna Immunotherapies Purchase | MT |
| 07-16 | Valerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies | MT |
Company Valuation: Valerio Therapeutics
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 52.01 | 38.52 | 15.64 | 25.42 | 11.55 | 67.46 |
| Change | - | -25.93% | -59.41% | 62.58% | -54.58% | 484.18% |
| Enterprise Value (EV) 1 | 43.74 | 30.57 | 11.19 | 29.61 | 26.93 | 74.72 |
| Change | - | -30.12% | -63.41% | 164.7% | -9.03% | 177.44% |
| P/E | 66.7x | -6x | -0.76x | -1.1x | -0.47x | -6.9x |
| PBR | 1.79x | 1.17x | 0.7x | 1.72x | -1.29x | 33.2x |
| PEG | - | 0x | -0x | 0.1x | -0.07x | 0.1x |
| Capitalization / Revenue | 29.3x | 9.48x | 10.8x | 14.1x | 6.44x | 26.2x |
| EV / Revenue | 24.6x | 7.53x | 7.75x | 16.4x | 15x | 29x |
| EV / EBITDA | -5.69x | -5.52x | -0.66x | -1.57x | -6.91x | 21.7x |
| EV / EBIT | -5.6x | -5.48x | -0.65x | -1.55x | -1.63x | -136x |
| EV / FCF | -4.87x | -4.16x | -3.83x | -3.02x | 4.67x | -101x |
| FCF Yield | -20.5% | -24.1% | -26.1% | -33.1% | 21.4% | -0.99% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 0.01 | -0.07 | -0.185 | -0.1505 | -0.16 | -0.02 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 1.776 | 4.062 | 1.443 | 1.8 | 1.793 | 2.573 |
| EBITDA 1 | -7.69 | -5.535 | -17.04 | -18.92 | -3.896 | 3.45 |
| EBIT 1 | -7.814 | -5.582 | -17.11 | -19.05 | -16.49 | -0.55 |
| Net income 1 | 1.089 | -5.937 | -19.56 | -20.34 | -23.93 | -4.898 |
| Net Debt 1 | -8.266 | -7.953 | -4.452 | 4.184 | 15.38 | 7.26 |
| Reference price 2 | 0.6670 | 0.4200 | 0.1408 | 0.1650 | 0.0750 | 0.1380 |
| Nbr of stocks (in thousands) | 77,977 | 91,722 | 111,059 | 154,077 | 153,972 | 488,848 |
| Announcement Date | 4/23/21 | 4/28/22 | 4/29/23 | 5/2/24 | 7/9/25 | 4/28/26 |
1EUR in Million2EUR
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 496M | |
| 35.74x | 12.95x | 26.26x | 0.55% | 1,119B | |
| 30.06x | - | - | 1.99% | 651B | |
| 33.82x | 7.82x | 16.26x | 2.59% | 468B | |
| 20.93x | 4.96x | 12.28x | 2.66% | 374B | |
| 22.59x | 5.81x | 14.4x | 2.75% | 302B | |
| 21.37x | 4.4x | 12.49x | 1.99% | 259B | |
| 27.79x | 7.17x | 12.73x | 2.3% | 238B | |
| 13.71x | 4.87x | 10.23x | 3.75% | 208B | |
| -44.65x | 6.45x | 25.18x | 2.26% | 181B | |
| Average | 17.93x | 6.80x | 16.23x | 2.31% | 380.04B | |
| Weighted average by Cap. | 25.51x | 8.51x | 18.70x | 1.89% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALVIO Stock
- Valuation Valerio Therapeutics
Select your edition
All financial news and data tailored to specific country editions
